We think Heron (HRTX) has a very good chance of approval by the FDA by the April 30, 2019 due date for its non-opioid pain med HTX-011....

BIopharma companies (Concert and Incyte) patent dispute.

(For a longer version of this article, with more detailed legal facts, please CLICK HERE.) Concert (CNCE) and Incyte (INCY) have been...

Sangamo (SGMO) provided an update today on its clinical programs, with its first clinical data for its Phase I Hemophilia A (gene...

Yesterday, Heron (HRTX) reported additional data for its opioid-free pain med candidate HTX-011 in a post-surgery setting. In the latest...